An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Alzheimer's disease affects about 250,000 older adults in Illinois. Experts and those who have had to take care of loved ones ...

Chris Hemsworth's touching road trip with his father Craig, who has "early-stage Alzheimer's," is chronicled in a National ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Novo Nordisk's blockbuster weight loss drug semaglutide failed to slow Alzheimer's progression in trials. The studies had ...